Harnessing the brain’s immune system to fight Alzheimer’s disease

CereSpir Overview

CereSpir was founded to complete the clinical development of CSP-1103 (formerly CHF 5074), a small molecule with the potential to slow disease in patients with Mild Cognitive Impairment (MCI), the earliest stage of Alzheimer’s disease.



CSP-1103 (formerly CHF 5074) has completed Phase 2 testing, and the Company is preparing a Phase 3 clinical program.

CSP-1103 is a small molecule with a unique mechanism of action capable of selectively reducing pro-inflammatory activities of microglial cells while increasing their ability to remove neurotoxic amyloid beta aggregates in the brain.


Latest News

Feb 21, 2014
Cerespir Incorporated Announces the Inauguration of its Clinical Advisory Board

Jan 10, 2014
Cerespir Incorporated Announces Chris Griffett Will Serve as Vice President, Regulatory Affairs

Nov 26, 2013
Cerespir Incorporated Appoints Richard Margolin, MD, as Vice President, Clinical Development